Smith & Nephew plc ADR Stock
Smith & Nephew plc ADR Stock
A loss of -2.040% shows a downward development for Smith & Nephew plc ADR.
Pros and Cons of Smith & Nephew plc ADR in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Smith & Nephew plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Smith & Nephew plc ADR | -2.040% | 3.521% | 5.000% | 23.529% | 5.000% | 11.364% | -16.477% |
| Smith & Nephew plc | -3.570% | 1.253% | 3.780% | 20.747% | 2.357% | 11.923% | -16.138% |
| Dexcom Inc. | -0.970% | 5.442% | 6.662% | -19.863% | 6.141% | -38.384% | -17.505% |
| Thermo Fisher Scientific Inc. | -1.540% | 1.209% | 8.248% | -0.359% | 6.758% | -1.567% | 29.108% |
Comments
Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew SNATS (NYSE:SNN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew plc (NYSE: SNN) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating on the stock.
Show more
Ratings data for SNN provided by MarketBeat
